Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Novacyt

Market Cap 29.13M 33.8M 26.82M 25.18M 47.28M 3.2B 47.78M 317M 123M 1.56B 127M 124M 5.42B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 31.09M 36.07M 28.62M 26.88M 50.46M 3.41B 50.99M 338M 132M 1.67B 135M 132M 5.79B EV / Sales 2026 *
1.02x
EV / Sales 2027 * 0.97x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-1.95%
1 week-12.42%
Current month-31.86%
1 month-25.28%
3 months+4.69%
6 months-11.45%
Current year+2.81%
1 week 0.39
Extreme 0.39
0.46
1 month 0.39
Extreme 0.39
0.7
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap.
03-29Buy

Chief Executive Officer

1,792 0.0025%
03-29Buy

Chief Executive Officer

56,438 0.0799%
03-29Buy

Chairman

15,228 0.0216%
Change 5-day change 1-year change 3-year change Capi.($)
-1.95%-12.42%-24.15%-15.23% 34.47M
+0.54%0.00%-38.74%-35.65% 548M
+0.40%+7.76%+257.55% - 528M
-0.42%+7.97%-33.02%+25.47% 142M
-5.14%-15.95%+48.99%+85.53% 125M
Average -1.31%-3.72%+42.12%+15.03% 275.66M
Weighted average by Cap. -0.19%-0.77%+83.78%-6.74%

Financials

2026 *2027 *
Net sales 30.52M 35.42M 28.11M 26.39M 49.55M 3.35B 50.07M 332M 129M 1.64B 133M 130M 5.68B 34.86M 40.45M 32.1M 30.14M 56.59M 3.82B 57.19M 379M 148M 1.87B 152M 149M 6.49B
Net income - -
Net Debt 1.96M 2.27M 1.8M 1.69M 3.18M 215M 3.21M 21.28M 8.29M 105M 8.52M 8.34M 364M 4.84M 5.62M 4.46M 4.19M 7.86M 531M 7.94M 52.69M 20.53M 260M 21.09M 20.64M 901M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-06-16 0.4020 -1.95% 99,312
26-06-15 0.4100 -2.84% 212,352
26-06-12 0.4220 +2.93% 264,754
26-06-11 0.4100 -2.38% 359,298
26-06-10 0.4200 -2.44% 529,702

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!